JPRN-jRCT2080223393已完成2 期
A PHASE 2, OPEN LABEL, MULTI-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Provided written informed consent
- •- Histologically confirmed prostate cancer with adenocarcinoma.
- •- Satisfy the following definition of castration resistance.
- •Castrate serum testosterone level:50 ng/dL or less
- •Bilateral orchiectomy or maintenance on androgen ablation therapy
- •with LHRH agonist or antagonist
- •Disease or PSA progression
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
排除标准
- •- A serious illness or medical condition.
- •- Hypersensitivity to any drugs similar to TAS-115 in structure or class.
- •- History of other primary malignancy in the last 5 years.
研究者
相似试验
已完成
2 期
A Phase 2 study of TAS-115 in patients with IPFIdiopathic pulmonary fibrosisJPRN-jRCT2080223842Taiho Pharmaceutical Co., Ltd.50
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients with Hydroxyurea-Resistant/ Intolerant Polycythemia Vera.Polycythemia Vera (PV)MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2017-000861-58-GBF. Hoffmann-La Roche Ltd48
进行中（未招募）
1 期
To Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed dose Combination (IV FDC) OfTiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid TumorsEUCTR2022-001157-23-GRF.Hoffmann-La Roche Ltd60
进行中（未招募）
1 期
To Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed dose Combination (IV FDC) OfTiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid TumorsSolid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2022-001157-23-CYF.Hoffmann-La Roche Ltd60
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics andPharmacodynamics of Idasanutlin Monotherapy in Patients with Hydroxyurea-Resistant/ Intolerant Polycythemia Vera.Polycythemia Vera (PV)MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2017-000861-58-ITF. HOFFMANN - LA ROCHE LTD.20